+91
पुढे सुरू ठेवण्याद्वारे, तुम्ही सर्व अटी व शर्ती* मान्य करता
कोड प्राप्त झाला नाही? पुन्हा पाठवा
STAR

स्ट्राईड्स फार्मा सायन्स शेअर किंमत

₹1,025.00 -47.8 (-4.46%)
52W कमी पासून 33.35% लाभ

31 जुलै, 2026 3:54 PM (IST)

स्ट्राईड्स फार्मा सायन्स लाईव्ह किंमत: ₹1,025.00. हे ₹1,074 वर उघडले आहे मागील बंद ₹1,073; इंट्राडे उच्च/कमी: ₹1,100/₹1,011. 50 आणि 200 DMA स्टँड केवळ ₹1,065.50/₹986.60.

स्ट्राईड्स फार्मा सायन्स परफॉर्मन्स

  • आजचे कमी
  • ₹1,011
  • आजचे उच्च
  • ₹1,100
  • 52 आठवडा कमी
  • ₹769
  • 52 आठवडा हाय
  • ₹1,231
  • ओपन प्राईस₹1,074
  • मागील बंद₹1,073
  • वॉल्यूम1,784,750
  • 50 डीएमए₹1,065.50
  • 100 डीएमए₹1,038.20
  • 200 डीएमए₹986.60

स्ट्राइड्स फार्मा सायन्स चार्ट

इन्व्हेस्टमेंट रिटर्न

  • 1 महिन्यापेक्षा जास्त -6.21%
  • 3 महिन्यापेक्षा जास्त -1.14%
  • 6 महिन्यापेक्षा जास्त + 16.88%
  • 1 वर्षापेक्षा जास्त + 17.26%

स्मार्ट इन्व्हेस्टिंग येथे सुरू होते स्थिर वाढीसाठी स्ट्राईड्स फार्मा सायन्ससह एसआयपी सुरू करा!

आता गुंतवा

स्ट्राईड्स फार्मा सायन्स फंडामेंटल्स फंडामेंटल्स म्हणजे फायनान्शियल डाटा जो कंपन्या तिमाही किंवा वार्षिक आधारावर रिपोर्ट करतात.

  • P/E रेशिओ
  • 15.4
  • PEG रेशिओ
  • 0.2
  • मार्केट कॅप कोटी
  • 9,448
  • P/B रेशिओ
  • 3
  • सरासरी ट्रू रेंज
  • 40.9
  • ईपीएस
  • 66.6
  • डिव्हिडंड उत्पन्न
  • 0.5
  • MACD सिग्नल
  • -12.1
  • आरएसआय
  • 40.55
  • एमएफआय
  • 34.45

नवीनतम स्टॉक न्यूज अपडेट्स

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY27

Strides Pharma Science Q1 PAT rises 56.7% to 165.5 cr

Revenue in the first quarter stood at 1,265.4 crore as against 1,119.7 crore in the year-ago period

Q1FY27 Quarterly Result Announced for Strides Pharma Science Ltd.

<h3><span style="font-size:16px;"><strong>फार्मास्युटिकल्स कंपनीने Q1FY27 परिणामांची घोषणा केली</strong></span></h3><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">एकत्रित फायनान्शियल हायलाईट्स: </strong></p><ul><li _ngcontent-ng-c3377174747="">Revenue from operations for Q1FY27 stood at Rs 12,654.07 million, reflecting a YoY growth of 13.01% from Rs 11,197.36 million in Q1FY26 and a QoQ decline of 4.39% compared to Rs 13,234.70 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Income reached Rs 12,702.97 million in Q1FY27, marking a YoY increase of 12.58% against Rs 11,283.19 million in Q1FY26, while showing a QoQ decrease of 4.60% from Rs 13,315.98 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit before exceptional items and tax for Q1FY27 was reported at Rs 1,377.04 million, representing a YoY rise of 5.67% from Rs 1,303.11 million in Q1FY26 and a QoQ decrease of 10.00% from Rs 1,530.07 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit before tax for the quarter was Rs 2,009.01 million, a YoY growth of 64.75% compared to Rs 1,219.44 million in Q1FY26 and a QoQ growth of 37.04% compared to Rs 1,466.02 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit for the period/year (attributed to owners of the Company) in Q1FY27 was Rs 1,569.14 million, showing a YoY growth of 57.53% from Rs 996.08 million in Q1FY26 and a QoQ growth of 23.61% from Rs 1,269.44 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Comprehensive Income for Q1FY27 was Rs 1,944.10 million, reflecting a YoY growth of 34.74% from Rs 1,442.82 million in Q1FY26 and a QoQ increase of 30.49% from Rs 1,489.85 million in Q4FY26.</li></ul><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">स्टँडअलोन फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3377174747="">Revenue from operations reached Rs 5,826.48 million in Q1FY27, representing a YoY increase of 16.85% from Rs 4,986.16 million in Q1FY26 and a QoQ decline of 3.81% from Rs 6,057.35 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Income for Q1FY27 was reported at Rs 5,841.23 million, up 16.74% YoY from Rs 5,003.74 million in Q1FY26 and down 4.20% QoQ from Rs 6,097.05 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit before tax for the quarter stood at Rs 847.58 million, marking a YoY growth of 416.72% over Rs 164.03 million in Q1FY26 and a QoQ growth of 219.74% over Rs 265.08 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Profit for the period/year reached Rs 729.28 million in Q1FY27, a YoY growth of 446.40% compared to Rs 133.47 million in Q1FY26 and a QoQ increase of 345.96% compared to Rs 163.53 million in Q4FY26.</li><li _ngcontent-ng-c3377174747="">Total Comprehensive Income for Q1FY27 was Rs 961.84 million, a YoY growth of 1,224.85% from Rs 72.60 million in Q1FY26. This parameter turned positive compared to a loss of Rs 117.37 million in Q4FY26.</li></ul><p _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">बिझनेस हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Restructuring and Demerger:</strong> The demerger of the Life Sciences and Digital Innovation business of Arco Lab Private Limited (a subsidiary) into Pivot Path Private Limited became effective on June 1, 2026. On June 27, 2026, the Board approved the dilution of the Group's controlling stake in Pivot Path to 19.95% for a consideration of Rs 1,000 million. This transaction resulted in a net gain of Rs 742.07 million (Consolidated) and Rs 764.01 million (Standalone), which has been recognized as an exceptional item.</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Product Recalls and Legal Provisions:</strong> The Group recorded provisions and expenses related to product recalls and litigations for Ranitidine, Losartan, and Testosterone. For Q1FY27, the consolidated exceptional items include Rs 110.10 million for product recall and settlement expenses. The Group maintains provisions of Rs 95.78 million specifically for testosterone recall-related evaluated settlements and expenses.</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Dividend:</strong> The Board of Directors has proposed a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, resulting in a cash outflow of approximately Rs 461 million, subject to shareholder approval.</li><li _ngcontent-ng-c3377174747=""><strong _ngcontent-ng-c3377174747="">Investment Property Sale:</strong> During FY26, the Company sold an investment property (land and building) for Rs 1,128.70 million, recording a profit of Rs 1,021.43 million as other income.</li></ul><p><strong>Badree Komandur, MD & Group CEO, said:</strong> “Strides delivered a steady start to FY27 with revenue growth of 13% YoY. Our investments in Ex-US Markets over the past few years are now yielding strong results, delivering 17% YoY growth and reinforcing the strength of our diversified business strategy. Our focus on execution and operating discipline enabled us to grow absolute gross margins by 14% YoY. EBITDA grew ~5% YoY to Rs 2,298 million, despite ~Rs 131 million impact from elevated operating and freight cost arising from the ongoing geopolitical situation. We remain focused on mitigating these pressures through continuous cost optimization initiatives. We reduced net debt by Rs 119m, with Net Debt-toEBITDA at 1.52x, despite significant working capital investments required to navigate the current business environment and growth. During the quarter, we unlocked Rs 1,000m of value through the divestment of our majority stake in Pivot Path, our captive GCC, while retaining meaningful participation in its future growth. We also improved our EcoVadis sustainability score to 68/100, a 19-point increase over last year. While the external environment remains dynamic, we remain focused on delivering sustainable and profitable growth.”</p><p><a class="lb" href="/marathi/get-document/post/pdf/5757151/" target="_blank">रिझल्ट PDF</a></p>

स्ट्राईड्स फार्मा सायन्स फायनान्शियल्स

स्ट्राईड्स फार्मा सायन्स टेक्निकल्स

ईएमए आणि एसएमए

वर्तमान किंमत
₹ 1,025.00
-47.8 (-4.46%)
pointer
  • बेरिश मूव्हिंग ॲव्हरेज 13
  • बुलिश मूव्हिंग ॲव्हरेज 3
  • 20 दिवस
  • ₹1,059.20
  • 50 दिवस
  • ₹1,065.50
  • 100 दिवस
  • ₹1,038.20
  • 200 दिवस
  • ₹986.60

प्रतिरोध आणि सहाय्य

1045.37 Pivot Speed
  • R3 1,168.50
  • R2 1,134.30
  • R1 1,079.60
  • S1 990.70
  • S2 956.50
  • S3 901.80

स्ट्राईड्स फार्मा सायन्स कॉर्पोरेट ॲक्शन्स - बोनस, स्प्लिट्स, डिव्हिडंड

तारीख उद्देश टिप्पणी
2026-07-31 तिमाही परिणाम
2026-05-18 ऑडिट केलेले परिणाम आणि अंतिम डिव्हिडंड
2026-01-30 तिमाही परिणाम
2025-10-31 तिमाही परिणाम
2025-07-29 तिमाही परिणाम
तारीख उद्देश टिप्पणी
2026-07-31 अंतिम ₹5.00 प्रति शेअर (50%) अंतिम डिव्हिडंड
2025-07-22 अंतिम ₹4.00 प्रति शेअर (40%) अंतिम डिव्हिडंड
2024-09-09 अंतिम ₹2.50 प्रति शेअर (25%) अंतिम डिव्हिडंड
2023-08-04 अंतिम ₹1.50 प्रति शेअर (15%) अंतिम डिव्हिडंड
2021-08-06 अंतिम ₹2.50 प्रति शेअर (25%) अंतिम डिव्हिडंड
स्ट्राईड्स फार्मा सायन्स डिव्हिडंड रेकॉर्ड पाहा Arrow

स्ट्राईड्स फार्मा सायन्स शेअरहोल्डिंग पॅटर्न

28.4%
28.28%
27.91%
8.73%
6.7%

स्ट्राईड्स फार्मा सायन्स विषयी

फार्मास्युटिकल उत्पादनांच्या विकास आणि उत्पादनामध्ये फार्मा विज्ञानाला चालना देते. अधिक पाहा
  • एनएसई सिम्बॉल
  • स्टार
  • बीएसई सिम्बॉल
  • 532531
  • एक्झिक्युटिव्ह डायरेक्टर, मॅनेजिंग डायरेक्टर, ग्रुप चीफ एक्झिक्युटिव्ह ऑफिसर
  • बद्री कोमांडूर
  • आयसिन
  • INE939A01011

फार्मा सायन्सला चालना देण्यासाठी सारखेच स्टॉक

स्ट्राईड्स फार्मा सायन्स एफएक्यू

स्ट्राईड्स फार्मा सायन्सची मार्केट कॅप 01 ऑगस्ट, 2026 रोजी ₹9447.7 कोटी आहे | 08:35

स्ट्राईड्स फार्मा सायन्सचा पी/ई रेशिओ 01 ऑगस्ट, 2026 रोजी 15.4 आहे | 08:35

स्ट्राईड्स फार्मा सायन्सचा पीबी रेशिओ 01 ऑगस्ट, 2026 रोजी 3 आहे | 08:35

The 52 week High & Low of Strides Pharma Science is ₹1231/₹768.6 respectively As on 01 August, 2026 | 08:35

मोफत डिमॅट अकाउंट उघडा

5paisa कम्युनिटीचा भाग बना - भारताचे पहिले लिस्टेड डिस्काउंट ब्रोकर.

+91

पुढे सुरू ठेवण्याद्वारे, तुम्ही सर्व अटी व शर्ती* मान्य करता

footer_form

अस्वीकृती: सिक्युरिटीज मार्केटमधील इन्व्हेस्टमेंट मार्केट रिस्कच्या अधीन आहेत, इन्व्हेस्टमेंट करण्यापूर्वी सर्व संबंधित डॉक्युमेंट्स काळजीपूर्वक वाचा. तपशीलवार अस्वीकृतीसाठी कृपया येथे क्लिक करा.

Q2FY23